DIVISLAB2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member DIVISLAB2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member DIVISLAB2020-01-012020-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2020-01-012020-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2020-01-012020-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DIVISLAB2020-01-012020-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2019-04-01 2020-03-31 2020-05-30 INR Lakhs Yearly Single segment Pharmaceuticals 2020-01-01 2020-03-31 Audited Consolidated 13897100000.00 767300000.00 14664400000.00 5456800000.00 99300000.00 -402000000.00 1731400000.00 4400000.00 497800000.00 2567100000.00 9954800000.00 4709600000.00 0.00 4709600000.00 538800000.00 288500000.00 827300000.00 0.00 3882300000.00 0.00 0.00 0.00 0.00 3882300000.00 -34000000.00 3848300000.00 0.00 0.00 530900000.00 2 14.62 14.62 0.00 0.00 14.62 14.62 1.tThe above Statement of consolidated financial results for the quarter and year ended 31st, March 2020, Statement of consolidated assets and liabilities and Statement of consolidated cash flows as at and for the year ended March 31, 2020 ('Consolidatd Statements') are prepared in accordance with Indian Accounting Standards ('lndAS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on June 6, 2020. The same also were audited by the Auditors of the Company and their report contains no qualification. n2.tThe consolidated results include the audited financial results of the wholly owned subsidiaries Divis Laboratories (USA) Inc and Divi’s Laboratories Europe AG. n3.tThe Group is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108. n4.tThe Group does not have any discontinued operations and the Profit for the period represents the Profits from continuing operations only. n5.tCurrent Tax Expense includes adjustment of tax reversals of earlier years amounting to Rs.3370 lakhs. n6.tThe Group considered the uncertainty relating to the COVID-19 pandemic in assessing the recoverability of its inventories, receivables and investments. As the group is into essential manufacturing service which is exempt from lockdown restrictions, there has been minimal impact in its operations and its supply chain. In this regard, the group has considered internal and external information while finalizing various estimates in relation to its financial statements upto the date of approval by the Board of Directors and has not identified any material impact on the carrying value of assets, liabilities or provisions. As the outbreak continues to evolve, the group will continue to closely monitor any material changes to future economic conditions. n7.tEffective April, 2019, the group has adopted Ind As 116, Leases. The Group has used the “modified retrospective approach” for transition from Ind As 17, “Leases”. The adoption of Ind As has resulted in recognition of Right-of-use assets and lease liabilities on transition date and from such date the nature of expenses for leasing arrangements has changed from lease rent in previous periods to depreciation on the Right-of-use assets and finance cost on corresponding lease liabilities. The adoption of Ind As 116 did not have a material impact on the results for the quarter and year ended March 31, 2020. n8.t*Figures for the quarter ended 31.03.2020 and corresponding quarter ended 31.03.2019 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years. n9.tThe Board of Directors of the company has declared and paid an interim dividend of Rs. 16 per share of face value Rs.2 each i.e., 800% for the financial year 2019-20. No final dividend is recommended. The total dividend payout for the current year amounted to Rs. 51206 lakhs including dividend tax. n10.tDetails of forex gain/(loss) are as given below: ntQuarter endedtYear Ended nt31.03.2020t31.12.2019t31.03.2019t31.03.2020t31.03.2019 nt(Audited)*t(Unaudited)t(Audited)*t(Audited)t(Audited) nForex gain/ (loss) t5710t1796t(611)t8211t3086 n Forex gain has been is included in Other Income and loss has been included in Other Expenses. n11.tFigures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current year’s classification. Single segment 2019-04-01 2020-03-31 Audited Consolidated 53944200000.00 1896300000.00 55840500000.00 21984100000.00 161100000.00 -1059800000.00 6210500000.00 61000000.00 1862400000.00 8426600000.00 37645900000.00 18194600000.00 0.00 18194600000.00 3927900000.00 501300000.00 4429200000.00 0.00 13765400000.00 0.00 0.00 0.00 0.00 13765400000.00 3500000.00 13768900000.00 0.00 0.00 530900000.00 2 72568300000.00 51.85 51.85 0.00 0.00 51.85 51.85 Other Expenses 2567100000.00 Other Expenses 8426600000.00